The company's financial position is strained by an accumulated deficit of -$995.9M, leaving the firm with minimal tangible assets and a heavy reliance on intangible intellectual property.
| Total Current Assets | 204.91M | 247.47M | 100.68M | 224.88M | 376.92M | 616.71M | 117.38M |
| Cash & Short-Term Investments | 184.15M | 226.69M | 69.35M | 200.64M | 371.99M | 591.42M | 114.99M |
| Cash Only | 184.15M | 226.69M | 69.35M | 200.64M | 92.08M | 542.22M | 114.99M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 279.92M | 49.19M | 0 |
| Accounts Receivable | 11.65M | 13.92M | 11.17M | 933K | 377K | 229K | 0 |
| Days Sales Outstanding | 72.24 | 95.09 | 160.6 | - | - | - | - |
| Inventory | 25.45M | 25.5M | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 1.05K | 2.48K | - | - | - | - | - |
| Other Current Assets | -16.34M | -23.11M | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 36.83M | 29.42M | 28.83M | 4.3M | 6.25M | 3.38M | 0 |
| Property, Plant & Equipment | 10.22M | 3.81M | 2.89M | 4.13M | 6.06M | 83K | 0 |
| Fixed Asset Turnover | 9.97x | 14.03x | 8.77x | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 26.61M | 25.61M | 25.94M | 175K | 191K | 3.3M | 0 |
| Total Assets | 241.74M | 276.88M | 129.51M | 229.18M | 383.17M | 620.09M | 117.38M |
| Asset Turnover | 0.30x | 0.19x | 0.20x | - | - | - | - |
| Asset Growth % | 183.01% | 113.78% | -43.49% | -40.19% | -38.21% | 428.27% | - |
| Total Current Liabilities | 31.66M | 34.16M | 61.98M | 50.29M | 25.03M | 62.06M | 13.07M |
| Accounts Payable | 2.02M | 13.74M | 10.45M | 7.95M | 1.52M | 5.78M | 8.15M |
| Days Payables Outstanding | 1.06K | 1.34K | 2.36K | - | - | - | - |
| Short-Term Debt | 1.59M | 1.31M | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 28.04M | 19.11M | 3.94M | 10.79M | 6.03M | 4.95M | 794K |
| Current Ratio | 6.47x | 7.24x | 1.62x | 4.47x | 15.06x | 9.94x | 8.98x |
| Quick Ratio | 5.67x | 6.50x | 1.62x | 4.47x | 15.06x | 9.94x | 8.98x |
| Cash Conversion Cycle | 61.27 | 1.24K | - | - | - | - | - |
| Total Non-Current Liabilities | 7.03M | 1.18M | 0 | 1.42M | 2.17M | 12K | 169.56M |
| Long-Term Debt | 7.03M | 1.18M | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 3.49M | 0 | 0 | 722K | 2.17M | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 700K | 1K | 12K | 169.56M |
| Total Liabilities | 38.69M | 35.34M | 61.98M | 51.71M | 27.2M | 62.07M | 182.63M |
| Total Debt | 8.63M | 2.49M | 1.3M | 2.17M | 3.72M | 0 | 0 |
| Net Debt | -175.53M | -224.19M | -68.05M | -198.48M | -88.35M | -542.22M | -114.99M |
| Debt / Equity | 0.04x | 0.01x | 0.02x | 0.01x | 0.01x | - | - |
| Debt / EBITDA | -0.11x | - | - | - | - | - | - |
| Net Debt / EBITDA | 2.20x | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | -5.25x | - | - |
| Total Equity | 203.05M | 241.54M | 67.54M | 177.47M | 355.97M | 558.02M | -65.25M |
| Equity Growth % | 474.95% | 257.63% | -61.94% | -50.15% | -36.21% | 955.21% | - |
| Book Value per Share | 0.66 | 1.40 | 0.57 | 1.62 | 3.29 | 5.04 | -0.59 |
| Total Shareholders' Equity | 203.05M | 241.54M | 67.54M | 177.47M | 355.97M | 558.02M | -65.25M |
| Common Stock | 28K | 28K | 12K | 11K | 11K | 11K | 1K |
| Retained Earnings | -995.88M | -954.48M | -901.99M | -732.07M | -533.43M | -292.11M | -65.32M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | -85K |
| Accumulated OCI | -37K | -41K | -5K | -13K | -272K | -8K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Rapid cash depletion risk
As reported in recent financial statements, Invivyd's total assets have experienced significant contraction, falling from $229.2M in 2023Q4 to $241.7M in 2026Q1, a trend that underscores the company's struggle to maintain a stable capital base while navigating the high-cost requirements of its antibody discovery platform.
The fluctuation in asset levels suggests that the company is heavily reliant on periodic capital infusions to offset persistent operating losses. Investors should monitor whether the current asset base can support the necessary R&D intensity required to keep pace with viral evolution without further dilutive financing.
Based on reported figures, the company's cash position has fluctuated significantly, dropping from a peak of $226.7M in 2025Q4 to $184.2M in 2026Q1, which indicates a narrowing runway for a business model that remains fundamentally dependent on external capital to fund its ongoing clinical development activities.
While the current ratio of 6.47 appears robust on the surface, it is largely a function of the current cash balance rather than operational efficiency. The rapid consumption of cash reserves suggests that liquidity could become a critical constraint if the company fails to secure consistent, non-dilutive revenue streams.
According to the company's balance sheet, retained earnings have plummeted to -$995.9M as of 2026Q1, a stark reflection of the massive, non-recoverable R&D expenditures required to sustain the firm's specialized antibody discovery efforts in a highly competitive and rapidly evolving infectious disease landscape.
The deep negative retained earnings position suggests that the company has yet to achieve a return on its invested capital, placing the entire burden of value creation on future, unproven commercial successes. This persistent erosion of equity warrants further investigation into the long-term viability of the current business model.
As evidenced by the balance sheet, the company maintains minimal PPE of $10.2M, which implies that the firm's value is almost entirely tied to intangible intellectual property that is subject to rapid obsolescence as SARS-CoV-2 variants continue to emerge and bypass existing therapeutic candidates.
The lack of tangible assets provides little collateral value, meaning the company's financial stability is entirely contingent on the clinical success of its lead antibody candidates. Investors should be wary that the absence of goodwill or significant physical assets leaves the balance sheet highly sensitive to any negative regulatory or clinical developments.
Quick answers to the most common questions about buying IVVD stock.
As of 2025, Invivyd, Inc. (IVVD) had total assets of $276.9M including $247.5M in current assets.
Invivyd, Inc. (IVVD) carries total debt of $2.5M, offset by $226.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Invivyd, Inc. (IVVD) has total shareholders' equity (book value) of $241.5M ($1.40 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Invivyd, Inc. (IVVD) reported a current ratio of 7.24x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.